Lv11
40 积分 2023-09-07 加入
396P Evaluation of MUC1-C/CD3 biparatopic-bispecific (BPBS) T cell engager as an immunotherapeutic agent for the treatment of MUC1-expressing metastatic breast cancer (mBC)
6小时前
已完结
CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
2个月前
已完结
Microspheres for controlled release drug delivery
2个月前
已完结
M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression
4个月前
已完结
NaCl enhances CD8+ T cell effector functions in cancer immunotherapy
9个月前
已完结
Sodium chloride in the tumor microenvironment enhances T cell metabolic fitness and cytotoxicity
9个月前
已完结
Blinatumomab: A historical perspective
11个月前
已完结
Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels
11个月前
已完结
Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
11个月前
已完结
Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab
11个月前
已完结
皖公网安备34019202002308
